Macquarie Hikes Zydus Lifesciences' Target Ahead Of Q1 Results; Bets On New Business Buildout To Drive Growth

Macquarie has maintained an 'overperform' rating on the stock and said that the near-term momentum will be carried on the back of existing businesses.